Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 63304-191; 0054-0401; 0054-0603; 14501-0068; 70436-013; 70771-1311; 68382-469; 0054-0400; 70436-036; 70771-1312; 0591-3660; 71335-1815; 68382-105; 46708-152; 70518-3195; 69766-025; 60687-607; 63304-192; 70771-1661; 68382-741; 72888-144; 46708-153; 53002-1801; 71335-1753; 71335-1975; 72888-143; 63629-7524; 70436-012; 0591-3659; 71335-1700; 0591-4060; 50090-4806
UNII NG99554ANW
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Homicidal ideation19.05.01.0080.000178%Not Available
Muscle tightness15.05.03.0070.000695%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.000571%Not Available
Bradyphrenia19.10.03.002; 17.03.03.0040.000784%Not Available
Dysstasia17.02.02.012; 15.03.05.011; 08.01.03.0890.000267%Not Available
Self-injurious ideation19.12.01.0070.000178%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Ocular discomfort06.08.03.0080.000392%Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.0010.000606%Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000267%Not Available
Depressive symptom19.15.02.0030.000695%Not Available
Affect lability19.04.01.0010.000749%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000178%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000606%Not Available
Bipolar disorder19.16.01.0030.000535%Not Available
Cognitive disorder17.03.03.003; 19.21.02.0010.000481%
Major depression19.15.01.0030.000446%Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.000392%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Hot flush08.01.03.027; 24.03.01.005; 21.02.02.0010.000998%
Neurological symptom17.02.05.0100.000178%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.0030.000446%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Eye movement disorder17.02.05.025; 06.05.02.0080.000178%Not Available
Limb discomfort15.03.04.0140.000606%Not Available
Intervertebral disc degeneration15.10.01.0020.000695%Not Available
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages